Masumi Ueda Oshima, MD, on, a Posttransplant GVHD Prophylaxis Strategy

February 24, 2025 By The ASCO Post Staff

Masumi Ueda Oshima, MD, of Fred Hutchinson Cancer Center, discusses findings from a phase II trial exploring the use of cyclosporine and sirolimus combined with mycophenolate mofetil or posttransplant cyclophosphamide as graft-vs-host disease (GVHD) prophylaxis.

Related Content